source
- Setara Biosciences raises $90 million Series A to advance Jazz-spun rare disease programsSetara Biosciences has been created to focus on a set of rare-disease assets that Jazz Pharmaceuticals retained after acquiring Actio Biosciences. The new company secured $90 million in Series A f…
- Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the biotech without a clinical program.